Looking for an academic partner for your discovery projects?
Looking for an academic partner for your discovery projects?
Ghent University offers a unique proposal: the collaboration between veterinarians, physicians and scientists from different disciplines present at Ghent University takes the research to a higher level and creates many opportunities for innovation. At our Faculty of Veterinary Medicine these innovations can be tested in our own facilities and on the target species.
Check what we can offer in these fields
Ghent University offers a unique proposal: the collaboration between veterinarians, physicians and scientists from different disciplines present at Ghent University takes the research to a higher level and creates many opportunities for innovation. At our Faculty of Veterinary Medicine these innovations can be tested in our own facilities and on the target species.
Check what we can offer in these fields
Therapeutics
A biological to treat pyoderma
A novel biological to treat pyoderma caused by Staphylococcus pseudintermedius (SP)
The biological is an engineered protein that can kill Staphylococcus pseudintermedius after topical administration on pyoderma lesions while enabling the natural skin microbiome to restore.
The biological has been validated in vitro against a panel of clinical strains from canine pyoderma and otitis externa patients. It has a good safety profile (no cytotoxicity) for application on canine skin and rapidly kills SP after topical application.
Proof of concept in patients
Two dogs with chronic recurrent pyoderma caused by a multidrug-resistant MRSP were used to assess the safety and effectiveness of our biological in an in vivo proof-of-concept (POC) study. For both patients, a significant improvement of the clinical appearance of the lesions was seen in the first 4 days with a corresponding decrease in CFU. At the end of the therapy, no adverse reactions could be identified, and all lesions had disappeared. After follow-up consultations, no new lesions have appeared in either of both patients.
Partnering
We are reaching out to partners who are interested in development and marketing of our novel biological.